A new sequencing-based method developed by Duke University's Kate Meyer is one of several that can detect RNA methylation without the use of antibodies.
The MacArthur Foundation has revealed this year's recipients of its 'genius' award, the New York Times reports.
The researchers repurposed type I variants of class 1 CRISPR systems to make them usable for DNA targeting and transcriptional control.
Exome sequencing and other molecular strategies led to a heterogeneous variant in the DNMT3A gene that appears to impact host epigenetic and immune features.
In PNAS this week: characterization of an alternatively spliced autism-linked gene, horizontal gene transfer in soil bacteria, and more.
James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.
The team reported that engineering a hairpin secondary structure onto the spacer region of sgRNAs can increase specificity by several orders of magnitude.
CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.